Tag: Blood Testing

Alzheimer’s disease Diagnosis and Plasma phospho-tau217-the ADAPT study

October 15, 2024 @ 12:00 pm – 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-10-15 Abstract: Exciting progress is being made in the early and accurate detection of Alzheimer’s disease (AD) using blood tests. The most promising of these blood markers is plasma p-tau217. Dr Ashvini Keshavan will first review the evidence for concordance of plasma p-tau217 with gold standard Alzheimer’s disease biomarkers (i.e. amyloid positron emission tomography and cerebrospinal fluid tests) and the current state of commercial availability of plasma phosphorylated tau biomarkers including comparisons of effect sizes. She will then proceed with describing the plan for ADAPT, a three-stage study including a UK multi-centre randomised controlled trial of disclosure of plasma p-tau217 results to patients and clinicians. From this study she aims to find out whether plasma p-tau217 helps to diagnose AD more quickly, more accurately and at an earlier disease stage in comparison to routine memory clinic diagnostic pathways, and we will obtain evidence for its cost effectiveness and acceptability to patients. Bio: Dr Ashvini Keshavan is a senior clinical research fellow and honorary consultant neurologist at the Dementia Research Centre, UCL Queen Square Institute of Neurology. A graduate of Trinity College, Cambridge, she completed postgraduate neurology training in London, and obtained her PhD in 2019 on Cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Her ongoing work examines these biomarkers in clinical and pre-clinical cohorts, aiming toward future application in more real-world settings, serving diverse populations. She is the joint primary investigator for the UK-wide ADAPT (Alzheimer’s disease Diagnosis and Plasma p-Tau217) study. This webinar is part of the 2024 Future Blood Testing Network+ webinar series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Multicorder – Enabling the Future of POC Diagnostics and Screening

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-09-12

Abstract:

Precision metabolomics and quantification for cost-effective rapid diagnosis of disease are the key goals in personalized medicine and point-of-care testing. At present, patients are subjected to multiple test procedures requiring large laboratory equipment. Here, we present a versatile single complementary metal–oxide–semiconductor chip forming a platform to address personalized needs through on-chip multimodal optical and electrochemical detection that will reduce the number of tests that patients must take. The chip integrates interleaved sensing subsystems for quadruple-mode colorimetric, chemiluminescent, surface plasmon resonance, and hydrogen ion measurements. These subsystems include a photodiode array and a single photon avalanche diode array and an array of ion sensitive field-effect transistors. The sensor arrays are distributed uniformly over an active area on the chip surface in a scalable and modular design. Bio-functionalization of the physical sensors yields a highly selective simultaneous multiple-assay platform in a disposable format. We have demonstrated its versatile capabilities through various applications such as CVD, prostate cancer diagnosis and bleeding disorders monitoring.

Bio:

Dr Chunxiao Hu is a Lecturer in Biomedical Engineering at the University of Glasgow. His research focuses on developing miniaturised portable microsystem platforms by using advanced technologies such as microfluidics, nanofabrication, surface functionalization for biomedical applications. Current projects include Highly integrated chemical sensors (electrical and optical) for multiple detection of biomarkers for early cancer diagnostics; CMOS based ISFET for fast antimicrobial susceptibility testing; Wearable biosensor for continuous monitoring of stroke; Microfluidic device for neurodegenerative diseases; Microfluidic device for electrophysiological analysis of drug uptake in nematodes.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Photonic Biosensing of Alzheimer’s Disease Biomarkers

July 5, 2024 @ 12:00 pm – 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-07-05 Abstract: A major issue facing the diagnosis of neurodegenerative disease is the availability of an accessible, scalable, and highly sensitive technology. Compelling evidence now suggests that the abundance of blood-based dementia biomarkers, including ß-amyloid (Aß) and tau, and their ratios, change considerably before clinical symptoms arise. Assessing these parameters via a straightforward blood test could facilitate early-stage diagnosis, recruitment of patients into clinical trials, and open a platform for at-home treatment monitoring. Current technologies for biomarker analysis are resource-intensive, rely on cerebrospinal fluid extraction, and are not widely adopted. Here, we demonstrate the detection of blood-based biomarkers using a next-generation, label-free photonic biosensor based on the principle of chirped guided mode resonance (GMR) spectroscopy. Our handheld GMR device is a low-cost optical biosensor suitable for the real-time, sensitive and parallel detection of dementia biomarkers. The technology utilizes wavelength scale grating structures to excite a standing wave that is sensitive to refractive index changes on the sensor surface. When target biomarkers bind to antibodies on the sensor surface, a refractive index change gives rise to a detectable shift in resonance wavelength. The chirped element of the GMR translates spectral information into spatial position, allowing biomarker binding to be detected by imaging the spatial position of the optical resonance on a simple camera detector. Our label-free technology outperforms competing modalities including surface plasmon approaches, has demonstrable sensitivity to pg/mL concentrations of low molecular weight protein biomarkers, offers a wide dynamic range, is mechanically and thermally stable, enables the real-time detection of at least eight biomarkers in parallel, and corrects for non-specific binding. By applying our biosensing approach to the detection of dementia biomarkers, we have demonstrated the real-time and quantitative detection of Aß in laboratory analytes, paving the way for further developments towards a blood test technology to support disease diagnosis, at-home treatment monitoring, and the democratization of testing. Bio: Dr Steven Quinn obtained an MPhys in Physics from the University of St. Andrews (2009) and an MSc in Radiation, Oncology and Biology from the University of Oxford (2010). After his PhD (St Andrews, 2013) and a postdoctoral position at the University of Glasgow (2013-2016), he took up a Lindemann Trust Fellowship at the Massachusetts Institute of Technology (2016-2017). In 2017, he was appointed to a Lectureship at the University of York and was awarded an Alzheimer’s Research UK Fellowship in 2019. Steven is now a Senior Lecturer, and his group uses a variety of analytical, biosensing and single-molecule techniques to detect and interrogate the structure and dynamics of biomolecules implicated in dementia. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Blood testing miniaturisation – opportunities, trends and challenges. Dr Al Edwards (University of Southampton)

May 17, 2024 @ 12:00 pm – 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-05-17 Abstract: Although the need for better diagnostics, especially point-of-care testing, is clear, the uptake of novel technology lags a long way behind demonstration and research papers. Using several case studies from my own research, alongside insight from current state-of-the art notably in diagnostics for microbiology and infection, I will outline the technological basis for bioassay miniaturisation (i.e. tiny blood tests) and discuss the diagnostics innovation pathway. Examples will include a review of >10 years developing microfluidic quantitative multiplex immunoassays that can measure multiple biomarkers in blood, as well as our latest developments in measuring platelet cell function directly in blood. Bio: With a background in fundamental immunology combined with expertise in biochemical engineering, Al Edwards is an interdisciplinary researcher focussed on solving current and future healthcare challenges using an engineering science approach that combines a range of fields from biology, biochemistry, chemistry and physics. He works at the interface between academic technology discovery and industrial development and have experience of both fundamental research and the commercialisation of new technology. The two main challenges he currently work on are the development of affordable microfluidic technology for clinical diagnostics and microbiology, and the engineering science of complex biologic therapeutics such as vaccines. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

A Radical Solution to the Visualization and Interaction with Timeline Structured Information: UHS Lifelines Electronic Patient Record Interface

May 3, 2024 @ 12:00 pm – 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/events/2024-05-03 Abstract: The ambitious NHS Digital Transformation Programme faces challenges in delivering efficient and intuitive information to health professionals. Since 2009, we have worked as a small team at University Hospital Southampton (UHS) Clinical Data Estate. Using e-data visualisation principles and a highly agile and iterative approach with minimal financial resources, we have developed a transformative approach to the Electronic Patient Record (EPR) interface. On UHS Lifelines, the timeframe is continuously incremental as new content accumulates. The interface opens near instantaneously in real time and documents from any time point are immediately accessible without scrolling through lists, menus, multiple frames and software subsystems, and the clinical history can be read subliminally to a valuable degree from the icon patterns. Despite initial constraints, the system evolved into a powerful application at the heart of UHS EPR. Additionally, it led to other software solutions, such as the SCR+ (Somerset Cancer Registry Enhanced) Multi-Disciplinary Team Module for cancer data management. We believe our approach has broad applicability beyond healthcare, potentially benefiting various sectors. We therefore appreciate all opportunities for collaboration to expand the project’s impact nationally and beyond. Bio: Mr David Rew is a Consultant General Surgeon in Southampton, Honorary Surgeon to the Faculty of Medicine of the University of Southampton and Visiting Professor in Clinical Informatics to Southampton Solent University. He served as the Editor in Chief of the European Journal of Surgical Oncology from 2003 to 2009. Since 2009, he has held the position of global Subject Chair for Medicine on the SCOPUS Content Selection Advisory Board, where he has appraised approximately 3,500 clinical journals. Mr Rew claims no specialist knowledge in haematology, blood testing or genomics, beyond being up to date with his Statutory and Mandatory blood transfusion module in the hospital virtual learning environment. ​For the past 15 years, David Rew has been the concept lead of a productive software development team at University Hospital Southampton, creating radical solutions to the electronic patient record, a whole-of-life breast cancer data set of more than 20,000 records, and a tool for the greater efficiency of cancer multidisciplinary teams, all of which systems sit at the heart of the unique University Hospital Southampton Clinical Data Estate. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Rapid Blood Tests: The Two-Year Manifesto. Dr Martin Peacock (Zimmer and Peacock Ltd)

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-04-17

Abstract: Zimmer and Peacock has worked on the development and manufacture of a platform intended to translate academic blood testing assays from the lab into the clinical setting, and onto the market. At ZP, for research to be impactful and sustainable, it does need to be presented in a form factor so that it can be easily used by clinicians and patients. In this webinar and live streaming demo, ZP will show how a scientific paper can easily become a clinical product. The policy at ZP is to translate science into regulatory approved products in 2 years or less.

Bio: Martin Peacock is an industrial bioelectrochemist with over twenty years of biosensor experience, having had industrial roles from Abbott Diabetes to GSK, and solving technical challenges from continuous glucose monitoring to RNA analysis. He is a Director at Zimmer and Peacock Ltd, a company that sees sensors as a critical part of various social and commercial revolutions, such as the Internet of Things (IoT), Sensor Web, and the Invitro Diagnostics Market (IVD). With over eight years of experience in this role, he lead a team of talented scientists and engineers who partner with academia and industry to develop and manufacture innovative sensors and medical diagnostics.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Routine cellular diagnostics: A platelet perspective? Dr Chris Jones (University of Reading)

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-03-26

Abstract: The idea of conducting tests for an infectious disease on the kitchen table would have seemed unimaginable only three years ago; now, it is a routine part of life in the UK. Similarly, measuring health markers such as heart rate or blood pressure used to involve a trip to your GP’s surgery; now, they are measured by your watch.  Routine testing of cellular function may be the next step, supplying data on cellular changes that occur before the presentation of symptoms or rapidly assessing the efficacy of therapies.  Platelets play a vital role in chronic and acute cardiovascular disease but also have roles in immunity, inflammation, cancer metastasis, Alzheimer’s disease and infections, such as dengue, HIV-1, malaria, and COVID-19.  In addition, they are easily obtained from subjects or patients, making them valuable biomarkers for changes in blood vessels associated with disease, ageing or therapy. This seminar will introduce the utility of platelets as a cellular biomarker and the progress we have made in designing tests that capture the function of these cells, both in the lab and at point-of-care.

Bio: Chris Jones is an Associate Professor of the Thrombosis and Heamostasis in the school of Biological Sciences at the University of Reading. Over two decades, he has designed and employed innovative platelet function assays to provide novel insights into platelet dysfunction. His lab has also developed analysis software for platelet activation assays and employed microfluidics, open hardware and smartphone technology to develop low-cost point-of-care platelet function assays. These new technologies have led to HaemAnalytica, a soon-to-be established spinout, which will provide complete platelet function analysis for clinical trials and diagnostics.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

“Digitally enabled blood testing for healthcare” mini-track was successfully organised at the 57th Hawaii International Conference on System Sciences (HICSS) in Honolulu on Jan 4th, 2024

by sk1r18, posted in Announcements, News

The mini-track was co-chaired by Prof. Weizi Li (University of Reading, UK), Prof. Kendall Ho (The University of British Columbia Columbia, Canada), Dr. Hector Zenil (Oxford Immune Algorithmics, UK), and Dr. Dionne Tannetta (Royal Berkshire NHS Foundation Trust, UK)

Dr. Tannetta’s talk showed how the Virtual Ward initiative in the UK is taking off and how it came about from the lessons learned from the Covid-19 pandemic where 131 patients remained at home closely monitored remotely under a very successful triaging clinical pathway. On the other hand, Prof. Li explained how an early-stage project to incorporate Generative AI in an arthritis triaging pathway, has led to an increase of accurate referral from primary to secondary care. Both projects show the promise and the future of AI and remote digital care in healthcare and medicine.

The Hawaii International Conference on System Sciences or 𝘏𝘐𝘊𝘊𝘚, is organised by the University of Hawai‘i – Shidler College of Business. It is known to be the longest-standing working scientific conference in Information Technology Management. Since 1968, 𝘏𝘐𝘊𝘊𝘚 has provided a highly interactive working environment for top scholars from academia and the industry from over 60 countries to exchange ideas in various areas of information, computer, and system sciences.

HICSS ranks second in citation ranking among 18 Information Systems (IS) conferences, third in value to the MIS field among 13 Management Information Systems (MIS) conferences, and second in conference rating among 11 IS conferences – more information can be found on the conference website: https://hicss.hawaii.edu.

The Future of Healthcare: Remote Blood Testing, Monitoring & AI

Registration Link: https://www.store.reading.ac.uk/conferences-and-events/henley-business-school/workshops/the-future-of-healthcare-remote-blood-testing-monitoring-ai

Formal Event Flyer: https://futurebloodtesting.org/fbtn2023/eventflyer

Description:

At the Future Blood Testing Network Plus, we are aiming to build a multi-disciplinary community to develop digital health technologies for remote, rapid, affordable and inclusive monitoring and personalised analytics. This two day workshop will feature speakers to discuss the future of healthcare, remote blood testing, monitoring and artificial intelligence (AI).

This event will take place at Leonardo Hotel Southampton (Formerly Jurys Inn). Both days will include lunch and coffee breaks, with day 1 also including a drinks reception with dinner.

NB: Due to venue policies on final numbers we cannot guarantee that we can cater to all dietary requirements after the 12th October. 

Event Costs

  • £30 – Physical Day Attendance (Includes lunch on both days, and dinner and drinks on day 1)
  • £50 – Accommodation (per night – Bed and Breakfast available on the 6th and 7th November)

Draft Agenda

Day 1 – 7th November

  • 10:00-10:30: Coffee & Registration
  • 10:30-12:00: Session 1: Landscape of Future Blood Testing – Session Chair: Dr Samantha Pearman-Kanza (University of Southampton)
    • 10:30-11:00: Future Blood Testing Network+ Overview and Recap – Professor Weizi (Vicky) Li (University of Reading)
    • 11:00-11:30: Remote Testing & AI – What’s Coming Next – Mr Frank Khan Sullivan (Enhanced Fertility)
    • 11:30-12:00: Landscape of Future blood testing in healthcare practice – Professor Dimitris Grammatopoulos (University of Warwick)
  • 12:00-13:00: Lunch & Photo session
  • 13:00-15:00: Session 2: Network Funded Projects  – Session Chair: Prof Weizi (Vicky) Li (University of Reading)
    • 13:00-13:30: Multi-modal deep learning approaches for identification of prognostic and diagnostic biomarkers – Dr Heba Sailem (Kings College London)
    • 13:30-14:00: FERRIQ: AI-Driven mapping of disease trajectories of patients with genetic iron overload to inform development of clinical decision support systems – Dr Fayyaz Minhas & Professor Dimitris Grammatopoulos (University of Warwick)
    • 14:00-14:15: Development of an implantable device for continuous monitoring of blood biomarkers – Dr Chenyang He (University of Nottingham)
    • 14:15-14:30: Blood microfluidics for point of care diagnostics – Professor Stavroula Balabani (UCL)
    • 14:30-14:45: Raman spectroscopy for remote blood testing – Dr Donna Arnold (University of Kent)
    • 14:45-15:00: Wearable Otological Measurement of Blood Analytes (WOMBA) – Dr Peter J. Christopher (University of Nottingham)
  • 15:00-15:15: Coffee Break
  • 15:15-17:15: Session 3: Adoption & Design for the Future of Digital Healthcare & Diagnostics: Design, data, NHS adoption and commercialisation
    • 15:15-15:30: Information Design in medical testing – Professor Sue Walker (University of Reading)
    • 15:30-17:15: Round Table (facilitated by Al, Sue, Mamta, Age)
      • Design: Professor Sue Walker (University of Reading)
      • Data: Professor Age Chapman (University of Southampton)
      • NHS adoption: Dr Mamta Bajre (Oxford Academic Health Science Network)
      • Commercialisation: Associate Professor Alexander Edwards (University of Southampton)
  • 17:10-17:30: Wrap Up
  • 17:30-19:00: Drinks Reception & Networking
  • 19:00: Conference Dinner

Day 2 – 8th November

  • 09:30-09:55: Coffee
  • 09:55-10:00: Welcome Back – Professor Weizi (Vicky) Li (University of Reading)
  • 10:00-12:30: Session 4: Future Blood Testing Research – Chair: Dr Mark Elliott (University of Warwick)
    • 10:00-10:30: Translating blood tests from the Academic Lab into the Clinical Setting – a Case Study – Dr Martin Peacock (Zimmer and Peacock Ltd)
    • 10:30-11:00: An immune score based on longitudinal blood testing – Dr Hector Zenil (Oxford Immune Algorithmics)
    • 11:00-11:30: Coffee Break
    • 11:30-12:00: Detection of drugs and biomarkers in healthcare using optical fibre sensors – Professor Serhiy Korposh (University of Nottingham)
    • 12:00-12:30: Squishing Biology to Advance Healthcare: A Journey from Saliva to Blood
      – Dr Robert Barker (University of Kent)
  • 12:30-13:30: Lunch

13-14/09/2022 – Future Blood Testing: Challenges & Opportunities

Eventbrite Link: https://fbtn-workshop-sept2022.eventbrite.co.uk 

Formal Event Flyer: https://futurebloodtesting.org/wp-content/uploads/2022/09/ReadingFlyerFinalVersion.pdf

Description:
At the Future Blood Testing Network Plus, we are aiming to build a multi-disciplinary community to develop digital health technologies for remote, rapid, affordable and inclusive monitoring and personalised analytics. This two day workshop will feature speakers to discuss the challenges and opportunities associated with this. We will also be launching our second funding call for both our technical landscape report, and for our pilot projects. This event will run as a hybrid event, the physical event will take place at the University of Reading in the Park House Building. Both days will include lunch and coffee breaks, with Day 1 also including a drinks reception with canapés, and dinner. Virtual attendees will be able to join us via Zoom.

NB: Due to venue policies on final numbers we cannot guarantee that we can cater to all dietary requirements after the 30th August. 

Posters & Pitches:
There will be an opportunity to submit a short pitch to present at this 2 day event. Please fill in our Pitch Form to submit a poster or pitch presentation.

  • Pitches will be one minute long with 1-2 slides. Delegates will introduce their expertise and collaborations they are looking for to develop a collaborative innovation project

NB: Pitch Presentations can take place virtually or physically. If you are planning on attending physically to give a pitch, you MUST have registered via our Eventbrite. You need to be registered in order to have your submission accepted. 

The deadline for submissions via this form is the 13th September (however we will email you as soon as we get your submission to tell you if you have been accepted or not).

Electronic copies of pitches should be sent to Dr Samantha Kanza s.kanza@reading.ac.uk by the 13th September. 

Agenda:

Day 1 – 13th September – Park House Building. The main workshop, refreshments, and the conference dinner will take place in the Meadow Suite, and the Drinks Reception will take place in Blandfords.

Time Session/Talk
09:30-10:00 Coffee & Registration
10:00-10:15 Future Blood Testing Network+ Overview
Prof Weizi (Vicky) Li (University of Reading)
Session 1: Chaired by Dr Robert Barker (University of Kent)
10:15-11:00 Transforming the UK’s diagnostics agenda after COVID-19 and grand challenges – Future Blood Testing Landscape report
Prof Dimitris Grammatopoulos (University Hospitals Coventry & Warwickshire, University of Warwick)
11:00-11:45 Measuring platelet function: new strategies for precision medicine to prevent thrombosis
Prof Jon Gibbins (University of Reading)
11:45-12:15 Coffee Break, Networking – There will also be a Group Photo
12:15-13:00 Lab services for a Web 3.0 world: how the next transformation will enable the democratisation of blood testing to have access and control of our own health
Dr Hector Zenil (University of Oxford & Oxford Immune Algorithmics)
13:00-14:00 Lunch
Session 2: Chaired by Prof Jeremy Frey (University of Southampton)
14:00-14:30 Remote blood monitoring for cancer patients- a preliminary landscape analysis
Beth Harvey (University of Reading)
14:30-15:00 Improving triaging from primary care into secondary care using heterogeneous data-driven hybrid machine learning: A real-world case study of decision support system using blood test & GP referral letters
Bing Wang and Prof Weizi (Vicky) Li (University of Reading)
15:00-15:45 Unmet Clinical Needs and Case Studies in Blood Testing
Prof Bryant Lin and Dr. Kevin Chang (Stanford University)
15:45-16:00 Coffee Break & Networking
Session 3: Chaired by Dr Samantha Kanza (University of Reading)
16:00-16:30 Collaborative Innovation Project funding launch
Dr Samantha Kanza (University of Reading)
16:30-17:00 One-minute pitch
Delegates introduce their expertise and collaborations they are looking for to develop a collaborative innovation project
17:00-19:00 Drinks Reception & Networking
19:00-20:00 Dinner & Networking

Day 2 – 14th September – Park House Building. The main workshop, and refreshments will take place in the Meadow Suite.

Time Session/Talk
09:30-10:00 Coffee & Registration
10:00-10:05 Welcome back
Prof Weizi (Vicky) Li (University of Reading)
Session 4: Chaired by Prof Serhiy Korposh (University of Nottingham)
10:05-10:35 Digital Solutions and Remote Monitoring in Real World Clinics
Dr Antoni Chan (Royal Berkshire NHS Foundation Trust)
10:35-11:05 ”Tiny Test Tubes” for affordable microfluidic blood measurements at the point of need
Dr Alexander Edwards (University of Reading)
11:05-11:20 Coffee Break & Networking
Session 5: Chaired by Claire Read (Healthcare Writer)
11:20-13:00 Panel discussion:
– Grand challenges of future blood testing
– Can NHS make use of remote blood monitoring and lessons learned from COVID testing
– Fake it till you make it? How do we achieve the future of blood testing without becoming the next Theranos?
Panel: Prof Neil Anderson, Dr Keith Arundale, Dr Antoni Chan, Dr Alexander Edwards, Prof Dimitris Grammatopoulos, Julie Hart
13:00-14:00 Lunch
Session 6: Chaired by Dr Mark Elliott (University of Warwick)
14:00-14:45 Artificial intelligence for identification of blood cells
Prof Huiyu Zhou (University of Leicester)
14:45-15:15 Precision Health and AI: improving health for everyone
Arjun Panesar (DDM Health)
15:15-15:30 Coffee Break & Networking
Session 7: Chaired by Dr Samantha Kanza (University of Reading)
15:30-16:15 One-minute pitch
Delegates introduce their expertise and collaborations they are looking for to develop a collaborative innovation project. Groups developed from the event present their concept and proposal outline 
16:15-16:30 Closing Remarks
Prof Weizi (Vicky) Li & Dr Samantha Kanza (University of Reading)